Merck and Moderna maintain a decade-old 50/50 collaboration on their personalized mRNA cancer vaccine intismeran, recently validated by positive Phase 3 data in high-risk melanoma that drove Moderna shares up over 90% and Merck shares higher in mid-August 2026. This successful partnership, including Merck’s modest 0.58% equity stake in Moderna, aligns incentives around joint development and profit-sharing rather than a full merger or acquisition. Merck has pursued separate deals, such as its March 2026 acquisition of Terns Pharmaceuticals, while focusing resources on Keytruda lifecycle management amid impending patent pressures. With no disclosed M&A discussions or regulatory filings, trader consensus reflects the low probability of a transformative transaction this year. Tail risks remain limited to unforeseen strategic pivots, such as a sudden capital need at Moderna or a broader sector consolidation, though current clinical momentum and balanced economics reduce those odds.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoSì
2% probabilità
NUOVO
NUOVO
31 dic 2026
Sì
2% probabilità
NUOVO
NUOVO
31 dic 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-old 50/50 collaboration on their personalized mRNA cancer vaccine intismeran, recently validated by positive Phase 3 data in high-risk melanoma that drove Moderna shares up over 90% and Merck shares higher in mid-August 2026. This successful partnership, including Merck’s modest 0.58% equity stake in Moderna, aligns incentives around joint development and profit-sharing rather than a full merger or acquisition. Merck has pursued separate deals, such as its March 2026 acquisition of Terns Pharmaceuticals, while focusing resources on Keytruda lifecycle management amid impending patent pressures. With no disclosed M&A discussions or regulatory filings, trader consensus reflects the low probability of a transformative transaction this year. Tail risks remain limited to unforeseen strategic pivots, such as a sudden capital need at Moderna or a broader sector consolidation, though current clinical momentum and balanced economics reduce those odds.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Mercato aperto: Aug 19, 2026, 3:58 PM ET
Volume
$411Data di fine
31 dic 2026Mercato aperto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-old 50/50 collaboration on their personalized mRNA cancer vaccine intismeran, recently validated by positive Phase 3 data in high-risk melanoma that drove Moderna shares up over 90% and Merck shares higher in mid-August 2026. This successful partnership, including Merck’s modest 0.58% equity stake in Moderna, aligns incentives around joint development and profit-sharing rather than a full merger or acquisition. Merck has pursued separate deals, such as its March 2026 acquisition of Terns Pharmaceuticals, while focusing resources on Keytruda lifecycle management amid impending patent pressures. With no disclosed M&A discussions or regulatory filings, trader consensus reflects the low probability of a transformative transaction this year. Tail risks remain limited to unforeseen strategic pivots, such as a sudden capital need at Moderna or a broader sector consolidation, though current clinical momentum and balanced economics reduce those odds.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$411Data di fine
31 dic 2026Mercato aperto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna maintain a decade-old 50/50 collaboration on their personalized mRNA cancer vaccine intismeran, recently validated by positive Phase 3 data in high-risk melanoma that drove Moderna shares up over 90% and Merck shares higher in mid-August 2026. This successful partnership, including Merck’s modest 0.58% equity stake in Moderna, aligns incentives around joint development and profit-sharing rather than a full merger or acquisition. Merck has pursued separate deals, such as its March 2026 acquisition of Terns Pharmaceuticals, while focusing resources on Keytruda lifecycle management amid impending patent pressures. With no disclosed M&A discussions or regulatory filings, trader consensus reflects the low probability of a transformative transaction this year. Tail risks remain limited to unforeseen strategic pivots, such as a sudden capital need at Moderna or a broader sector consolidation, though current clinical momentum and balanced economics reduce those odds.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti